Myomo, Inc.

As of November 6, 2017, Myomo, Inc. is considered overvalued and risky due to its high Price to Book Value of 4.94, negative EV to EBIT and EV to EBITDA ratios, a return on equity of -26.80%, and significant underperformance with a year-to-date return of -86.96% compared to the S&P 500's 12.22%.

As of November 6, 2017, Myomo, Inc. is considered overvalued and has a "risky" valuation grade due to significant financial distress indicated by a price-to-book ratio of 4.94, an EV to EBITDA of -18.39, and a year-to-date return of -64.75%, contrasting sharply with healthier peers like Sally Beauty and Herbalife.

As of May 8, 2025, the market trend is bearish with moderate strength, indicated by bearish MACD readings, Bollinger Bands, and moving averages, despite some short-term bullish signals from the RSI.

As of March 2022, the management team of Myomo, Inc. includes Steve Kelly as Founder, Chairman, President, and COO, and Paul Gudonis as CEO and Director.

Myomo, Inc. is a U.S. medical device company that develops myoelectric orthotics for individuals with neurological disorders. As of March 2025, it reported net sales of $10 million and a net loss of $3 million, with a market cap of approximately $98.94 million.

As of Jun 18, Myomo, Inc. has a market capitalization of 98.94 million, with net sales of 38.63 million and a net profit of -5.82 million over the last four quarters. Shareholder's funds total 24.71 million, and total assets are valued at 42.24 million.